NCI to Press FDA For Quicker Drug Approval, Relaxation Of Survival Impact Requirement
In Brief: Tom Hall Names CMMI VP For Clinical Affairs; Rabson, Fauci Names to Institute Of Medicine
Consensus Panel Say Surgery, Radiation Both Effective For Clinically Local Prostate Cancer
Bristol To Support Grants For Studies On Drug Resistance
DCT Board Approves Concept For BRMP Master Agreement
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - The Galleri MCD vote: What FDA asked its advisors to ignore
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says
